Hungary Pharmaceuticals & Healthcare Q1 2020
We maintain a muted long-term outlook for the Hungarian pharmaceutical due to a range of factors, principally driven bya lack of funding within the healthcare system. The government spends significantly less on the health system than the EU average,both in absolute terms and as a share of GDP. Although it remains one of the larger and more-developed markets in the Central andEastern Europe region, growth opportunities will remain considerably below its regional peers. Nonetheless, innovative medicinesales will be supported by a rising chronic disease burden driven by Hungary’s ageing, albeit declining, population.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook